Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
暂无分享,去创建一个
R. Gray | C. Sotiriou | S. Loi | M. Piccart | C. Denkert | G. Pruneri | S. Demaria | S. Adams | S. Badve | S. Michiels | R. Salgado | A. Vingiani | D. Drubay | F. André | H. Joensuu | J. Lemonnier | M. Lacroix-Triki | M. Dieci | P. Francis | P. Kellokumpu-Lehtinen | E. Munzone | K. Gray
[1] Peter Schmid,et al. LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 , 2017 .
[2] C. Perou,et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer , 2017, Science Translational Medicine.
[3] Krishna R. Kalari,et al. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer , 2017, Breast Cancer Research and Treatment.
[4] J. Luke,et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.
[5] Carsten Denkert,et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group , 2016, Modern Pathology.
[6] R. Gelber,et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 , 2016, Breast Cancer Research and Treatment.
[7] Richard D Riley,et al. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges , 2016, BMJ.
[8] L. Zitvogel,et al. Microbiome and Anticancer Immunosurveillance , 2016, Cell.
[9] Carsten Denkert,et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.
[10] G Pruneri,et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] H. Wildiers,et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[13] M. Mathieu,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[15] Carsten Denkert,et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Ying Wang,et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.
[18] Molin Wang,et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F M Blows,et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Laura J. Esserman,et al. Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.
[23] L. Mauriac,et al. Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer. , 2009 .
[24] Xueri Li,et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .
[25] Tianxi Cai,et al. Evaluating Prediction Rules for t-Year Survivors With Censored Regression Models , 2007 .